These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23289359)

  • 1. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.
    Abramson JS; Takvorian RW; Fisher DC; Feng Y; Jacobsen ED; Brown JR; Barnes JA; Neuberg DS; Hochberg EP
    Leuk Lymphoma; 2013 Sep; 54(9):1915-20. PubMed ID: 23289359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
    Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
    Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.
    Blum KA; Hamadani M; Phillips GS; Lozanski G; Johnson AJ; Lucas DM; Smith LL; Baiocchi R; Lin TS; Porcu P; Devine SM; Byrd JC
    Leuk Lymphoma; 2009 Mar; 50(3):349-56. PubMed ID: 19263294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Foss FM; Parker T
    Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.
    Jacoby MA; Martin MG; Uy GL; Westervelt P; Dipersio JF; Cashen A; Stockerl-Goldstein K; Vij R; Luo J; Reineck T; Bernabe N; Abboud CN
    Am J Hematol; 2014 May; 89(5):487-92. PubMed ID: 24415560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
    Nabhan C; Davis N; Bitran JD; Galvez A; Fried W; Tolzien K; Foss S; Dewey WM; Venugopal P
    Cancer; 2011 Apr; 117(7):1490-7. PubMed ID: 21425150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
    Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
    J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.
    Simko SJ; Tran HD; Jones J; Bilgi M; Beaupin LK; Coulter D; Garrington T; McCavit TL; Moore C; Rivera-Ortegón F; Shaffer L; Stork L; Turcotte L; Welsh EC; Hicks MJ; McClain KL; Allen CE
    Pediatr Blood Cancer; 2014 Mar; 61(3):479-87. PubMed ID: 24106153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
    O'Connor D; Sibson K; Caswell M; Connor P; Cummins M; Mitchell C; Motwani J; Taj M; Vora A; Wynn R; Kearns PR
    Br J Haematol; 2011 Aug; 154(4):482-5. PubMed ID: 21689087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.
    Claxton D; Erba HP; Faderl S; Arellano M; Lyons RM; Kovacsovics T; Gabrilove J; Huebner D; Gandhi PJ; Kantarjian H;
    Leuk Lymphoma; 2012 Mar; 53(3):435-40. PubMed ID: 21877883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clofarabine in relapsed lymphoma: what is the optimal dose?
    Nabhan C
    Leuk Lymphoma; 2009 Jul; 50(7):1230-1; author reply 1232-4. PubMed ID: 19557647
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
    Zeidan AM; Ricklis RM; Carraway HE; Yun HD; Greer JM; Smith BD; Levis MJ; McDevitt MA; Pratz KW; Showel MM; Gladstone DE; Gore SD; Karp JE
    Br J Haematol; 2012 Jul; 158(2):198-207. PubMed ID: 22594769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.
    Barba P; Sampol A; Calbacho M; Gonzalez J; Serrano J; Martínez-Sánchez P; Fernández P; García-Boyero R; Bueno J; Ribera JM
    Am J Hematol; 2012 Jun; 87(6):631-4. PubMed ID: 22431002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clofarabine in the treatment of elderly patients with acute myeloid leukemia.
    Aleem A; Anjum F; Algahtani F; Iqbal Z; Alsaleh K; Almomen A
    Asian Pac J Cancer Prev; 2013; 14(2):1089-92. PubMed ID: 23621192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
    Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
    Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.
    Zoellner AK; Fritsch S; Prevalsek D; Engel N; Hubmann M; Reibke R; Rieger CT; Hellmuth JC; Haas M; Mumm F; Herold T; Ledderose G; Hiddemann W; Dreyling M; Hausmann A; Tischer J
    Bone Marrow Transplant; 2015 May; 50(5):679-84. PubMed ID: 25642765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
    Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
    Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.
    Soni S; Abdel-Azim H; McManus M; Nemecek E; Sposto R; Woolfrey A; Frangoul H
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1134-1141. PubMed ID: 28396162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.